ACAD (66) AMLX (38) OGN (61) VKTX (44) ⌘ Pro Terminal →

Parabilis Medicines Inc. (PBLS) — RQD Stock Rating Cockpit

$28.70 +1.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $28.74

Parabilis Medicines Inc. (PBLS) carries a Roarable Rating of C- (Hold) with 60/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $3.50B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $28.74 (+0.15%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 2.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 60/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.4% avg 90D alpha vs SPY • 53.5% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+0.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBLS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (60/100 Composite)

🔍 WHY PBLS SCORES 60/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 30% of 52W Range • RSI-14 at 48.5 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+13/20 pts (22% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$27.48-17.2% Next Q

Q2 (-2Q)

Grade C$22.75+7.4% Next Q

Q3 (-1Q)

Grade C$24.44+17.4% Next Q

Current

Grade C-$28.70+0.4% Hist 90D α

Trajectory: C- (52) → C- (60)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PBLS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 60/100 (C-) score, PBLS faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($32.96) or 200D SMA ($32.22) invalidates the momentum regime and cuts Target Base ($28.96) toward Bear Floor ($22.59).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBLS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PBLS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 60%NO 40%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

48.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE30% OF RANGE

L: $23$28.70H: $42

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● NEUTRAL

Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: D+RQD 22 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on PBLS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (62)

22/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like PBLS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PBLS Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PBLS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.18%📐 HORIZONTAL RANGE

2026-10-30O $28.59H $28.74L $27.48C $28.70VOL 814.0K

RES: $43.99SUP: $22.44SMA50: $32.96SMA200: $32.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBLS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBLS Butterfly Map → + Track PBLS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PBLS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBLS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PBLS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBLS)

Health Care Rank #201 of 1016 ⚔️ ACAD vs PBLS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBLS vs. ACAD, AMLX, OGN, VKTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Parabilis Medicines Inc. (PBLS) ranks #201 by composite RQD confidence (60/100, grade C-) and #194 by equity capitalization ($3.50B). Within this direct 5-issuer industry benchmark cohort, ACAD leads on earnings valuation at 9.1x trailing P/E, while OGN leads on capital efficiency and profitability with 24.9% ROIC and 53.3% gross margin. ACAD currently holds the highest overall quantitative score in the immediate peer group at 66/100 (C+) compared with PBLS at 60/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PBLS ACTIVE Parabilis Medicines Inc.	C-	60/100	—	—	—	+1.88%	$3.50B	Benchmark Subject
ACAD ACADIA Pharmaceuticals Inc.	C+	66/100	9.1x	91.7%	7.9%	+2.17%	$3.58B	/acad-vs-pbls →
AMLX Amylyx Pharmaceuticals Inc.	D-	38/100	—	—	-35.0%	+2.17%	$3.60B	/amlx-vs-pbls →
OGN Organon & Co.	C-	61/100	19.4x	53.3%	24.9%	+0.22%	$3.63B	/ogn-vs-pbls →
VKTX Viking Therapeutics Inc.	D	44/100	—	—	-35.0%	+5.92%	$3.38B	/vktx-vs-pbls →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001657677

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Parabilis Medicines Inc. (PBLS) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, PBLS closed FY2025 with $80.8M in total assets against $600.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$80.8M	$600.0K

3. PBLS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBLS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Parabilis Medicines Inc. (NASDAQ: PBLS) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 60/100 at a spot price of $28.70 (+1.88% 1D, market cap $3.50B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, PBLS ranks #201 in composite RQD confidence.

How does PBLS compare to ACAD and AMLX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBLS carries a Roarable C- (60/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ACAD (ACADIA Pharmaceuticals Inc.) holds a C+ grade (66/100 RQD, P/E 9.1x, ROIC 7.9%, cap $3.58B) and AMLX (Amylyx Pharmaceuticals Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $3.60B). Among the 5-stock peer group, ACAD leads on earnings multiple (9.1x) while OGN leads on capital efficiency (24.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PBLS?

Per PBLS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001657677), Parabilis Medicines Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $80.8M in total assets and $600.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PBLS trading relative to its 50-day, 200-day, and 52-week technical levels?

PBLS last traded at $28.70 (+1.88% on volume of 844,759 shares), positioning the stock -12.92% below its 50-day simple moving average ($32.96) and -10.92% below its 200-day simple moving average ($32.22). Across its 52-week range of $22.66 to $42.49, PBLS sits at the 30.5% percentile with a 14-day RSI of 48.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($25.11 to $32.29).

PBLS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PBLS stock right now?

Parabilis Medicines Inc. (PBLS) currently earns a Roarable Rating of C- (Hold — HOLD) with 60/100 RQD Confidence. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

What is PBLS's 12-month price target and RQD AI Jury consensus?

PBLS's 12-month base price target is $28.96 (range $22.59 to $44.61), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PBLS RQD Cockpit PBLS 12M Forecast PBLS Earnings & Move PBLS Dividends & DRIP PBLS Insiders & 13F PBLS Whale Options PBLS Profit Sankey PBLS News & Why